

T2

Isolated bc₁ Complex as a Screening System for Potential Anti-Malaria DrugsA. Müllebn^a, T. Rosenau^b, A. Patel^b, L. Gille^a^aResearch Institute of Biochemical Pharmacology and Toxicology, University of Veterinary Medicine Vienna,^bDepartment of Chemistry, University of Natural Resources and Applied Life Sciences, Vienna, Austria

Malaria is responsible for 1–2 million deaths per year. Therefore, the development of new and inexpensive anti-malaria drugs is required. The mitochondrial bc₁ complex in protozoa was identified as a suitable drug target for malaria antibiotics. The mechanism is based on a stronger inhibition of the bc₁ complex in plasmodia than in mammalian bc₁ complex. Aim of this study was to set up a model system for the screening of compounds with possible anti-malaria activity. Due to the sequence homology of the bc₁ complex in plasmodia and *Saccharomyces cerevisiae*, its bc₁ complex can be used as a model. Therefore, the membrane-bound bc₁ complex was isolated via a detergent-based solubilization and chromatographic purification from bovine heart mitochondria and from yeast mitochondria as models for mammals and plasmodia, respectively. The measurement of the quinol : cytochrome c oxidoreductase activity in both complexes gave turnover numbers of about 200 s⁻¹ indicating a functional enzyme preparation. Titration of the enzymatic activity with stigmatellin revealed an IC₅₀ of 2.15 ± 0.28 nM for bovine and 1.80 ± 0.19 nM for the yeast bc₁ complex indicating the non-selective toxicity of this compound. However, if the only available anti-malaria drug for this target atovaquone was used, an IC₅₀ of 12.4 ± 1.08 μM for bovine and 4.52 ± 0.35 μM for yeast bc₁ complex was obtained. In contrast to stigmatellin, the drug atovaquone inhibits the yeast complex three times more than the mammalian bc₁ complex. These basic biochemical data indicate that the model consisting of isolated bovine and yeast bc₁ complex is suitable for the identification of new anti-malaria drugs.